
FASN Inhibitor – TVB-2640
Indication – NASH
Phase 2
FASN Inhibitor – TVB-2640
Indication – Oncology
Phase 2
FASN Inhibitor – TVB-3567
Indication – Undisclosed
Preclinical
Posters & Publications
FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models
Scientific Reports
Read More